All Trials

A Phase 2 Trial of Atezolizumab and Cabozantinib in Adolescents and Young Adults With Recurrent/Metastatic Osteosarcoma (TACOS)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study for adolescents and young adults (≥12) with histologically confirmed recurrent/metastatic or unresectable osteosarcoma after standard chemotherapy, requiring measurable disease and ECOG 0–2. Treatment is atezolizumab (anti–PD-L1) plus cabozantinib (oral multi–TKI targeting MET/VEGFR2/AXL) given in 21-day cycles until progression or intolerance.

ClinicalTrials.gov ID: NCT05019703

A Phase 1/2a, Open-Label, Dose Escalation and Expansion Study of the Safety and Tolerability of T3011 Administered Via Intratumoral Injection as a Single Agent and in Combination With Intravenous Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors requiring at least one injectable lesion (ECOG 0–1) receive intratumoral T3011—an engineered oncolytic HSV‑1 expressing IL‑12 and an anti‑PD‑1 antibody—either as monotherapy in melanoma, HNSCC post‑platinum/PD‑(L)1, sarcoma, or cSCC, or combined with IV pembrolizumab in previously treated metastatic NSCLC without EGFR/ALK alterations. Excludes patients with uninjectable disease, high‑risk injection sites, active autoimmune disease requiring immunosuppression, active HSV, significant cardiopulmonary disease, CNS metastases, or active viral infections.

ClinicalTrials.gov ID: NCT04370587

Carboplatin and Cabazitaxel Versus 177Lu-PSMA-617 in Patients With Aggressive, Metastatic Castrate-resistant Prostate Cancer (CATCH-177)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with aggressive, PSMA-PET–positive mCRPC after at least one AR pathway inhibitor (often post-docetaxel) are randomized to cabazitaxel plus carboplatin versus 177Lu-PSMA-617 radioligand therapy (binds PSMA to deliver beta-emitting lutetium-177). Eligible patients have high-risk features (e.g., visceral disease, ≥5 bone mets, lower PSMA SUVmean, or TP53/PTEN/RB1 alterations) and ECOG 0–2.

ClinicalTrials.gov ID: NCT06738303

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Men with de novo metastatic prostate adenocarcinoma who complete 22–28 weeks of guideline-concordant ADT-based systemic therapy without progression (castrate T, PS 0–1) are randomized to continue systemic therapy alone versus adding definitive treatment of the primary (radical prostatectomy or definitive prostate radiation). Systemic therapy may include surgical or medical castration (LHRH agonists/antagonist), first-generation antiandrogens, and/or abiraterone; docetaxel allowed only during induction.

ClinicalTrials.gov ID: NCT03678025

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic castration-resistant prostate cancer on continuous androgen suppression, including post–novel hormonal therapy and often post-taxane, receive xaluritamig (AMG 509), a STEAP1×CD3 bispecific T‑cell engager, as IV or SC monotherapy or in combination with abiraterone or enzalutamide. Excludes small cell/neuroendocrine histology and untreated CNS disease; aims to define dosing while assessing early antitumor activity.

ClinicalTrials.gov ID: NCT04221542

A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Open-label rollover for men with prostate cancer who are deriving benefit from ongoing enzalutamide-based therapy in a prior Astellas/Medivation trial, continuing the same regimen without change. Participants may remain on enzalutamide monotherapy or continue prior combinations (enzalutamide plus abiraterone/prednisone or plus leuprolide); enzalutamide is an androgen receptor signaling inhibitor.

ClinicalTrials.gov ID: NCT02960022

Phase II Trial of Targeted Radiation With no Castration for Mcrpc

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with PSMA-avid oligometastatic castration-resistant prostate cancer (≤10 lesions) who have received at least one ARSI stop ongoing ADT and receive comprehensive lesion-directed SBRT plus 177Lu‑PSMA‑617 radioligand therapy; they are then randomized to observation versus physiologic testosterone replacement. Excludes visceral (liver/brain) metastases and neuroendocrine histology.

ClinicalTrials.gov ID: NCT06084338

Phase II Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with metastatic castration-resistant prostate cancer who progressed on at least 12 weeks of abiraterone plus prednisone receive abiraterone with dexamethasone, with or without metronidazole, to test whether switching steroids and suppressing androgen-producing gut anaerobes can restore abiraterone sensitivity. Metronidazole is investigational here for microbiome modulation; key exclusions include steroid contraindications, significant hepatic dysfunction, prolonged QTc, uncontrolled diabetes, active infection/IBD, and recent antibacterial therapy.

ClinicalTrials.gov ID: NCT06616597

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Men with biochemical recurrence after prostatectomy, ECOG 0–2, candidates for salvage prostate bed/pelvic nodal RT and short-term ADT, are randomized by PET status: PET-negative receive standard salvage EBRT + 6 months ADT with or without 6 months apalutamide (androgen receptor inhibitor); PET-positive receive the same intensified systemic therapy with apalutamide with or without metastasis-directed RT to PET-avid extrapelvic sites. Primary endpoint is progression-free survival.

ClinicalTrials.gov ID: NCT04423211

A Phase Ib Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Men with mCRPC (ECOG 0–1) post–novel hormonal therapy and with PSMA-positive disease receive 177Lu-PSMA-617 combined with oral cabozantinib, a multi–tyrosine kinase inhibitor (targets MET/VEGFR2/AXL/RET) to assess safety and preliminary efficacy. Excludes prior PSMA RLT or cabozantinib and patients with significant cardiovascular, bleeding, CNS, or GI risk.

ClinicalTrials.gov ID: NCT05613894